dacuronium has been researched along with ganirelix in 1 studies
| Studies (dacuronium) | Trials (dacuronium) | Recent Studies (post-2010) (dacuronium) | Studies (ganirelix) | Trials (ganirelix) | Recent Studies (post-2010) (ganirelix) |
|---|---|---|---|---|---|
| 17 | 8 | 0 | 240 | 92 | 76 |
| Protein | Taxonomy | dacuronium (IC50) | ganirelix (IC50) |
|---|---|---|---|
| Gonadotropin-releasing hormone receptor | Homo sapiens (human) | 0.0036 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, D; Choi, J; Koo, YA; Lee, B; Lee, E; Park, HJ | 1 |
1 other study(ies) available for dacuronium and ganirelix
| Article | Year |
|---|---|
Altered vascular endothelial growth factor expression during GnRH antagonist protocol in women of reproductive age with normal baseline hormone profiles.
Topics: Adult; Chorionic Gonadotropin; Estradiol; Female; Fertility Agents, Female; Fertilization in Vitro; Follicle Stimulating Hormone, Human; Follicular Fluid; Gonadotropin-Releasing Hormone; Hormone Antagonists; Hormones; Humans; Luteinizing Hormone; Oocyte Retrieval; Ovulation Induction; Pancuronium; Pregnancy; Pregnancy Rate; Progesterone; Retrospective Studies; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |